Plasma cfDNA in Glioblastoma-Response

Stephen J Bagley^{1

2

3}, Erica L Carpenter^{4

2

3}

Affiliations

¹ Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Sbagley@pennmedicine.upenn.edu.
² Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
³ Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
⁴ Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

Comment

Stephen J Bagley et al. Clin Cancer Res. 2020.

. 2020 May 1;26(9):2276.

doi: 10.1158/1078-0432.CCR-20-0285.

Stephen J Bagley^{1

2

3}, Erica L Carpenter^{4

2

3}

¹ Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Sbagley@pennmedicine.upenn.edu.
² Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
³ Glioblastoma Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
⁴ Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors declare no potential conflicts of interest.

Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.
Bagley SJ, Nabavizadeh SA, Mays JJ, Till JE, Ware JB, Levy S, Sarchiapone W, Hussain J, Prior T, Guiry S, Christensen T, Yee SS, Nasrallah MP, Morrissette JJD, Binder ZA, O'Rourke DM, Cucchiara AJ, Brem S, Desai AS, Carpenter EL. Bagley SJ, et al. Clin Cancer Res. 2020 Jan 15;26(2):397-407. doi: 10.1158/1078-0432.CCR-19-2533. Epub 2019 Oct 30. Clin Cancer Res. 2020. PMID: 31666247 Free PMC article.
Plasma cfDNA in Glioblastoma-Letter.
Takayasu T, Esquenazi Y, Ballester LY. Takayasu T, et al. Clin Cancer Res. 2020 May 1;26(9):2275. doi: 10.1158/1078-0432.CCR-19-4159. Clin Cancer Res. 2020. PMID: 32358024 No abstract available.

1. Bagley S, Nabavizadeh SA, Mays J, Till JE, Ware J, Levy S, et al. Clinical utility of plasma cell-free DNA in adult patients with newly diagnosed glioblastoma - a pilot prospective study. Clin Cancer Res 2020; 26: 397–407. - PMC - PubMed
1. Lanman RB, Mortimer SA, Zill OA, Sebisanovic D, Lopez R, Blau S, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One 2015; 10: e0140712. - PMC - PubMed
1. Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin Cancer Res 2018; 24: 3539–3549. - PubMed
1. Stetson D, Ahmed A, Xu X, Nuttall BRB, Lubinski TJ, Johnson JH, et al. Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance. JCO Precis Oncol 2019; 3: 1–9. - PubMed